Human Endocrine Gland Vascular Endothelial Growth Factor Recombinant

///Human Endocrine Gland Vascular Endothelial Growth Factor Recombinant

Human Endocrine Gland Vascular Endothelial Growth Factor Recombinant


accession P58294

Source Optimized DNA sequence encoding Human EG-VEGF mature chain was expressed in Escherichia Coli.
Molecular weight Native human EG-VEGF is generated by the proteolytic removal of the signal peptide, This molecule has a calculated molecular mass of approximately 10 kDa. Recombinant EG-VEGF is a monomer protein consisting of 86 amino acid residue subunits,and migrates as an approximately 10 kDa protein under reducing conditions in SDS-PAGE.
Purity >98%, as determined by SDS-PAGE and HPLC
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation Recombinant EG-VEGFwas lyophilized from a.2 μm filtered PBS solution.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers.
Storage The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

Biological Process Angiogenesis
Molecular function Growth-factor
Molecular function Mitogen


Expression of PROK1 and PROKR1 mRNA in human uteroplacental tissues at term.

40 nmol/L PROK1
  • PROK1 mRNA expression is elevated in myometrium and placenta during labor at term compared with the tissues collected at term before the onset of labor .